Clinical Implications of Genomic Discoveries in Lung Cancer.

N Engl J Med

From the Translational Cancer Therapeutics Laboratory, Francis Crick Institute, and the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, University College London Hospitals and Cancer Institute, London (C.S.); and the Division of Oncology, Department of Medicine, and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis (R.G.).

Published: May 2016

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1504688DOI Listing

Publication Analysis

Top Keywords

clinical implications
4
implications genomic
4
genomic discoveries
4
discoveries lung
4
lung cancer
4
clinical
1
genomic
1
discoveries
1
lung
1
cancer
1

Similar Publications

Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.

Cancer Nurs

January 2025

Author Affiliations: Departments of Physiotherapy (Drs Heredia Ciuró, Martín Núñez, Navas Otero, Calvache Mateo, Torres Sánchez, and Valenza) and Nursing (Dr Granados Santiago), Faculty of Health Sciences, University of Granada, Granada, Spain.

Background: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness.

View Article and Find Full Text PDF

Identifying Adolescent and Young Adults' Preferences for Oncology Symptom Management Clinical Trial Participation.

Cancer Nurs

January 2025

Author Affiliations: Department of Health and Clinical Sciences, University of Michigan School of Nursing (Dr Knoerl and Mss Smener and Grandinetti); Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School (Drs Fecher, Henry, Karimi, Pettit, and Schuetze); Pediatric Hematology/Oncology, C.S. Mott Children's Hospital (Dr Walling); and School of Social Work, University of Michigan (Dr Zhang), Ann Arbor; and College of Nursing, The University of Tennessee, Knoxville (Dr Barton).

Background: Most studies to date exploring facilitators and barriers to adolescent and young adults' (AYAs') participation in clinical trials have been focused on external factors to AYAs' participation or recruitment strategies.

Objective: The purpose of this mixed-methods study was to determine AYA cancer survivors' preferences for oncology symptom management clinical trial participation.

Methods: Semistructured interviews and conjoint analysis were conducted to clarify potential attributes (eg, characteristics) and levels (eg, value of the characteristic) that may be important to AYA cancer survivors when considering clinical trial participation (n = 19).

View Article and Find Full Text PDF

Lewy body (LB) pathology is present as a co-pathology in approximately 50% of Alzheimer's disease (AD) dementia patients and may even represent the main neuropathologic substrate in a subset of patients with amnestic impairments. However, the degree to which LB pathology affects the neurodegenerative course and clinical phenotype in amnestic patients is not well understood. Recently developed α-synuclein seed amplification assays (αSyn-SAAs) provide a unique opportunity for further investigating the complex interplay between AD and LB pathology in shaping heterogeneous regional neurodegeneration patterns and clinical trajectories among amnestic patients.

View Article and Find Full Text PDF

Aging is associated with disrupted sleep patterns, such as fragmented sleep and reduced efficiency, leading to negative health outcomes. There is evidence of a bidirectional relationship between sleep and gut microbiota, which plays a key role in the gut-brain axis and overall health. However, studies on this relationship in older adults have limited generalizability and show conflicting results, highlighting the need for further research.

View Article and Find Full Text PDF

Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System.

Int J Clin Pharm

January 2025

Department of Pharmacy, Medical Supplies Center of Chinese, PLA General Hospital, 28 Fu Xing Road, Beijing, 100853, China.

Background: Drug-induced hypofibrinogenemia has received increasing scrutiny; however, the specific drugs involved remain poorly characterized. Hypofibrinogenemia can have significant clinical implications, including increased bleeding risks.

Aim: This study aimed to utilize the FDA Adverse Event Reporting System (FAERS) to identify and analyze drugs frequently implicated in drug-induced hypofibrinogenemia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!